Doctoral student develops a new cross-disciplinary therapy for pancreatic cancer

May 9, 2014 by John Wallace
David Durrant, doctoral candidate in the Department of Biochemistry and Molecular Biology

(Medical Xpress)—David Durrant is a doctoral candidate in the Department of Biochemistry and Molecular Biology at the Virginia Commonwealth University School of Medicine. He conducts research in the lab of Rakesh Kukreja, Ph.D., Eric Lipman Professor in Cardiology at the VCU Pauley Heart Center and a member of the Developmental Therapeutics research program at VCU Massey Cancer Center. While Kukreja is renowned in the field of cardiology, Durrant's focus is on cancer. With Kukreja's guidance, he is making significant progress testing a new combination therapy for pancreatic cancer, and many in the field of pharmacology are taking notice.

The novel therapy combines the widely used chemotherapy agent doxorubicin with an experimental drug known as BEZ235. Durrant presented his research at the American Society for Pharmacology and Experimental Therapeutics (ASPET) conference in April in San Diego, and he has also been awarded a travel grant to attend the World Congress of Basic and Clinical Pharmacology (WCP) in Cape Town, South Africa in July.

Below, Durrant discusses his research, his upcoming travels and how he got into the field of .

Working in the lab of a cardiologist, how did you get the idea to combine these two drugs to treat cancer?

Doxorubicin has been used to treat a variety of cancers for quite some time. However, shortly after it was introduced it became apparent that it had the potential to damage cardiac tissue. Dr. Kukreja's research involves finding new ways to prevent from cancer therapies, and he has studied the effects of doxorubicin. Unfortunately, tumors often develop a resistance to doxorubicin, and the benefits of increasing the dosage are outweighed by the potential for heart damage.

Cancer cells often initiate several key survival mechanisms to counteract the deadly effects of doxorubicin. These mechanisms are carried out through signaling pathways, which are groups of molecules that work together to control cellular functions. When exposed to doxorubicin, activate the PI3K/AKT/mTOR signaling pathway, which has been shown to promote cell growth and survival. Additionally, proteins known as ATP-binding cassette transporters literally pump doxorubicin out of the cancer cells.

In 2006, a drug named BEZ235 was the first PI3K inhibitor to enter clinical trials. BEZ235 works by blocking signaling through the PI3K/AKT/mTOR pathway. When I first entered the Ph.D. program, Dr. Kukreja wanted to study different kinase inhibitors, like BEZ235, in combination with doxorubicin. While we knew there was the possibility for heart damage, we thought it might be possible to make doxorubicin more effective.

What kind of results are you seeing?

So far, we've tested the therapy on human cells grown in the lab and in some basic animal models. The results have been very encouraging. The combination of doxorubicin and BEZ235 caused significantly more cancer cell death than treatment with doxorubicin alone. Not only did we find that the cells were undergoing apoptosis, a form of cell suicide, the results showed that there was a significantly higher amount of doxorubicin in the cancer cells. These results were surprising because they demonstrated that, in addition to blocking survival mechanisms through the PI3K/AKT/mTOR pathway, BEZ235 was disrupting the cell's ability to get rid of the doxorubicin.

Why did you decide to focus on pancreatic cancer?

Originally, we were working with breast cancer since doxorubicin is such a widely used treatment. We actually started looking into pancreatic cancer after the death of Steve Jobs. Sadly, pancreatic cancer has the lowest overall survival rate of all major cancers while being the fourth-leading cause of cancer death. Because most cases are diagnosed in later stages, it is often impossible to surgically remove the entire tumor. There have been very few improvements in patient outcomes in the past few decades, so there is a major need for new therapies and treatment options.

What do you see as the next steps?

I'm really hoping we will be able to translate our findings to a clinical trial and potentially bring a new therapy to pancreatic cancer patients. We will continue to perform experiments using cell lines to document how the therapy works. We will also develop more advanced animal models to better test the therapy's effectiveness. If the results are promising enough, I'm hopeful that we can find a clinical partner and start a phase 1 trial. Since doxorubicin is already approved for the treatment of a variety of cancers and BEZ235 is currently being tested in clinical trials, I'm optimistic that we could get the trial approved if our experiments are successful enough.

What most excites you about your upcoming travels?

I've been to a few conferences already, and the most interesting part for me is always meeting new people and being able to exchange ideas. These events are amazing opportunities to learn about cutting-edge research in a variety of fields.

WCP in South Africa is a very prestigious conference that only happens every four years. I'm extremely honored to take part in it. Dr. Kukreja encouraged me to apply for the travel grant, and I was shocked to receive it. Honestly, just traveling to South Africa is something I never thought I would be able to do, so I'm really looking forward to the experience. I can't wait to meet people from all over the world and be exposed to their perspectives.

Where do you see your career taking you, and do you have any advice for students looking to enter the field of cancer research?

As far as what's next for me, I literally ask myself that question every day. I'm not going to rule out any options. I will likely complete at least one postdoctoral fellowship. Ideally, I would like to continue in academic research, preferably in Richmond, but I know that may not be an option since the funding environment is so competitive.

I think those most suited to this type of research have to be naturally curious. It takes a different sort of mind, and it's certainly not for everyone. Those who excel typically have a desire to figure things out and will work through challenges. While the basic knowledge is important, much of the required skills can't be taught in a book. My best advice is to confront challenges by applying yourself and making sure you understand exactly what you're trying to accomplish. Sometimes the most important discoveries are found in analyzing failures.

Explore further: Novel drug cocktail may improve clinical treatment for pancreatic cancer

Related Stories

Novel drug cocktail may improve clinical treatment for pancreatic cancer

May 1, 2014
Pancreatic cancer is the fourth leading cause of cancer deaths in the U.S. and has the lowest overall survival rate of all major cancers (~6%). With current treatment options being met with limited success it is anticipated ...

Drug trio improved effectiveness of cancer treatment, protected heart

November 6, 2012
Combining cancer medication with a drug for erectile dysfunction and one for heart transplants helped kill cancer cells and protected the heart from damage, in a study presented at the American Heart Association's Scientific ...

New drug combination therapy developed to treat leukemia

April 17, 2013
A new, pre-clinical study by researchers at Virginia Commonwealth University Massey Cancer Center suggests that a novel drug combination could lead to profound leukemia cell death by disrupting the function of two major pro-survival ...

Drug combination therapy causes cancer cells to 'eat themselves'

November 5, 2013
Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain ...

Doxorubicin-associated mitochondrial iron accumulation promotes cardiotoxicity

January 2, 2014
Doxorubicin is a widely used as a component of chemotherapy regimes; however, the use of doxorubicin is associated with severe cardiotoxicity. It is unclear exactly how doxorubicin promotes cardiotoxicity, but it has been ...

Dietary inorganic nitrate may reduce heart dysfunction caused by powerful anti-cancer drug

May 19, 2011
Virginia Commonwealth University researchers have found that nutrient supplementation, like the kind that is found in leafy greens, spinach and lettuce, may reduce the damage to the heart caused by a powerful anti-cancer ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.